Global Diabetic Kidney Disease Market Size Study, by Drug Class (Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, Antioxidant Inflammation Modulator, Angiotensin-Converting Enzyme (ACE) Inhibitors, Others), by Route of Administration (Oral,

Global Diabetic Kidney Disease Market Size Study, by Drug Class (Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, Antioxidant Inflammation Modulator, Angiotensin-Converting Enzyme (ACE) Inhibitors, Others), by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecasts 2022-2032

Global diabetic kidney disease market is valued at approximately USD 2.89 billion in 2023 and is anticipated to grow at a steady CAGR of 4.8% over the forecast period from 2024 to 2032, reaching a projected market size of USD 4.21 billion by 2032. Diabetic kidney disease, a severe complication of diabetes, occurs when high blood sugar levels cause damage to the kidneys' blood vessels. This leads to impaired kidney function, resulting in the accumulation of waste in the body and potentially severe health issues. As the prevalence of diabetes continues to rise globally, the diabetic kidney disease market is witnessing significant growth, driven by the increasing awareness of the disease, the availability of advanced treatment options, and developments in diagnostic tools and renal replacement therapies.

The market's growth is primarily fueled by the sharp increase in the global diabetic population, which correlates with a higher incidence of diabetic kidney disease. As lifestyle habits change and physical activity decreases, more individuals are being diagnosed with diabetes, elevating their risk of developing kidney complications. The aging global population further exacerbates this trend, as older individuals are more susceptible to chronic conditions, including diabetic kidney disease, due to long-standing diabetes. Healthcare systems are now faced with the challenge of managing this growing burden, which is driving the demand for effective treatments and early diagnostic tools.

However, the market faces several challenges, including the high cost of treatment devices and a lack of awareness in low-income regions. These barriers can limit access to care, especially in developing countries where healthcare resources are limited. Despite these challenges, the market presents lucrative opportunities, particularly in regions experiencing rapid economic growth and urbanization, such as Asia-Pacific and Latin America. The rising prevalence of diabetes in these regions, coupled with increased healthcare spending, is expected to drive market expansion over the forecast period.

North America has been the dominant region in the global diabetic kidney disease market, with the U.S. holding the largest share due to its high prevalence of diabetes and access to advanced healthcare. The region's economic capabilities and well-developed healthcare infrastructure have led to significant investments in research and development, resulting in innovative treatments and early adoption of new therapies. Meanwhile, the Asia-Pacific region is emerging as the fastest-growing market, driven by rapid urbanization, increasing awareness of diabetes-related complications, and the availability of affordable generic drugs.

Major market players included in this report are:
AstraZeneca
Boehringer Ingelheim
Janssen Pharmaceuticals
Bristol Myers Squibb
GSK
Novo Nordisk
Eli Lilly and Company
Merck & Co.
Sanofi
AbbVie
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
Lupin
Aurobindo Pharma
Takeda Pharmaceutical Company Limited

The detailed segments and sub-segment of the market are explained below:
By Drug Class
• Angiotensin Receptor Blockers (ARBs)
• Calcium Channel Blockers
• Antioxidant Inflammation Modulator
• Angiotensin-Converting Enzyme (ACE) Inhibitors
• Others
By Route of Administration
• Oral
• Parenteral
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
Latin America
• Brazil
• Mexico
• RoLA
Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2031.
• Annualized revenues and regional-level analysis for each market segment.
• Detailed analysis of the geographical landscape with country-level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of the competitive structure of the market.
• Demand-side and supply-side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.